Search results
• Ampligen is a broadly applicable immune therapy that has the potential to be used in a wide range of indications • Generally well-tolerated with over 100,000 IV doses in humans • Ampligen has Orphan Drug Status in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Metastatic Melanoma, Renal Cell Carcinoma,
Phase I/II colorectal cancer trial of Ampligen plus rIFNα-2b and celecoxib showed increase ratio of CXCL10 (CTL-attractant) to CCL22 (Treg-attractant) and increase ratio of CTL/Treg markers
Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-
Ampligen is being evaluated as a potential treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), COVID-19, Long COVID-19, and multiple types of cancers. Alferon is a...
safety of Ampligen treatment combined with standard of care (SOC) versus SOC alone following First-line therapy in subjects with locally advanced pancreatic adenocarcinoma. Trial Phase & Type
3 wrz 2023 · PRIMARY OBJECTIVE• To compare the efficacy of Ampligen® versus control group / no treatment following FOLFIRINOX in subjects with Locally Advanced Pancreatic Adenocarcinoma.SECONDARY OBJECTIVE• To evaluate safety and tolerability of Ampligen®…
Ampligen is being evaluated as a potential treatment for COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and multiple types of cancers. Alferon is a natural interferon...
